Stock analysts at Stifel Nicolaus started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $29.00 price target on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 81.25% from the company’s current price.
Contineum Therapeutics Stock Up 1.8 %
Shares of CTNM stock opened at $16.00 on Tuesday. Contineum Therapeutics has a 12 month low of $13.90 and a 12 month high of $16.05.
Contineum Therapeutics Company Profile
Further Reading
- Five stocks we like better than Contineum Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- Can Disney Stock Triple Before 2030?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The 3 Hottest Insiders Buys This Month
- 3 Ways To Invest In Coffee, Other Than Drinking It
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.